MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/biomedicines14091953

Медицинская библиотека · Biomedicines · 2026

Basic Periodontal Treatment Improves Periodontal Inflamed Surface Area Without Adverse Events in Patients Receiving Direct Oral Anticoagulants: A Retrospective Clinical Study with an Animal Model.

Fujimori Ryousuke, Taniguchi Yuri, Ouhara Kazuhisa, Miyauchi Shunsuke, Matsuda Shinji, Kuwahara Naoya, Ueda Shoya, Hou Yitong, Shimizu Masaru, Tari Misako, Kono Shoko, Iwata Tomoyuki, Shintani Tomoaki, Kajiya Mikihito, Miyauchi Mutsumi, Nakano Yukiko, Mizuno Noriyoshi

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

The optimal management of periodontal treatment in patients receiving direct oral anticoagulants (DOACs) remains poorly established, and bleeding concerns may lead clinicians to delay or limit treatment. We evaluated the clinical efficacy and safety of nonsurgical periodontal treatment in patients receiving DOAC therapy.

Methods

This retrospective study included 67 patients receiving continuous DOAC therapy (edoxaban, apixaban, dabigatran, or rivaroxaban) who underwent nonsurgical periodontal treatment without drug discontinuation. Pocket probing depth, bleeding on probing, the periodontal inflamed surface area (PISA), the periodontal epithelial surface area (PESA), and serum inflammatory cytokine levels were evaluated. A ligature-induced-periodontitis mouse model was also used to assess the effect of apixaban on alveolar bone loss.

Results

Nonsurgical periodontal treatment significantly reduced the PISA (42.9%) and PESA (10.8%) in the overall DOAC cohort, with no postoperative bleeding complications. Significant reductions in periodontal parameters were seen in the edoxaban (PISA: 44.2%, PESA: 10.9% reduction), apixaban (PISA: 45.6%, PESA: 11.7% reduction), and dabigatran (PISA: 61.3%, PESA: 16.1% reduction) groups, with no significant changes in the rivaroxaban group. Baseline PISA was positively correlated with baseline serum levels of interleukin-4 (r = 0.33), interleukin-1 beta (r = 0.29), interleukin-6 (r = 0.25), and interleukin-10 (r = 0.30). In the mouse model, apixaban administration did not aggravate ligature-induced alveolar bone loss.

Conclusions

Basic periodontal treatment appears to be safe and effective for patients prescribed DOACs and may reduce local periodontal inflammation, resulting in systemic inflammatory burden. These findings support proactive periodontal intervention in patients receiving DOAC therapy, regardless of the specific anticoagulant used.

Для цитирования: Fujimori Ryousuke, Taniguchi Yuri, Ouhara Kazuhisa, Miyauchi Shunsuke, Matsuda Shinji, Kuwahara Naoya, Ueda Shoya, Hou Yitong, Shimizu Masaru, Tari Misako, Kono Shoko, Iwata Tomoyuki, Shintani Tomoaki, Kajiya Mikihito, Miyauchi Mutsumi, Nakano Yukiko, Mizuno Noriyoshi. Basic Periodontal Treatment Improves Periodontal Inflamed Surface Area Without Adverse Events in Patients Receiving Direct Oral Anticoagulants: A Retrospective Clinical Study with an Animal Model.. Biomedicines. 2026. DOI: 10.3390/biomedicines14091953.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.